Lisa Cook sues Trump over firing attempt, emergency hearing set
HACKENSACK, NJ - Champions Oncology (NASDAQ:CSBR), a company specializing in translational oncology research with a market capitalization of $109.72 million, has obtained a license to utilize radioactive materials in its preclinical studies. The license, granted today, enables the firm to conduct in-house research with a variety of radionuclides, enhancing its capabilities in developing and evaluating targeted radiotherapeutics. According to InvestingPro data, the company has demonstrated strong operational performance with a 19.03% revenue growth over the last twelve months.
The new license positions Champions Oncology to combine radionuclide-based therapeutic testing with its extensive patient-derived xenograft (PDX) models, which are considered highly clinically relevant. The integration of these two platforms is expected to advance the development of radiopharmaceuticals with improved translational precision.
Ronnie Morris, CEO of Champions Oncology, emphasized the importance of the license, stating, "This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics." He highlighted the potential for the company’s PDX platform to drive progress in the field of radiopharmaceutical development. The market appears to recognize this potential, as InvestingPro data shows the stock has achieved an impressive 98.49% return over the past six months, with additional ProTips available for subscribers regarding the company’s growth prospects and valuation metrics.
Champions Oncology’s program will assist drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides. This initiative is part of the company’s broader commitment to providing end-to-end oncology R&D solutions, from preclinical to clinical stages, to biopharmaceutical organizations globally.
With the largest and most annotated bank of PDX and primary hematological malignancy models, Champions Oncology offers a comprehensive range of services to support the discovery and development of new cancer treatments. The company’s proprietary platforms and bioanalytical capabilities are designed to deliver high-quality data and insights for oncology drug development programs. Financial metrics support the company’s strong market position, with a healthy gross profit margin of 51.58% and positive net income expectations for the current year. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US equities including Champions Oncology.
This announcement is based on a press release statement from Champions Oncology. For more information on the company’s services and capabilities, interested parties are directed to the company’s website and contact page.
In other recent news, Champions Oncology reported its Q1 2025 earnings, significantly exceeding analyst expectations. The company achieved an earnings per share (EPS) of $0.36, far surpassing the forecast of -$0.01, and recorded a quarterly revenue of $17 million, which was above the anticipated $12.93 million. Additionally, the company has been successful in securing a data licensing deal worth $4.5 million, with the potential to expand to $8 million. This deal reflects the company’s strategic focus on leveraging AI and machine learning to enhance its oncology data offerings. Analyst Matt G. Hewitt from Craig-Hallum responded to these developments by raising the price target for Champions Oncology from $8.00 to $12.00 and maintaining a Buy rating. The analyst highlighted the company’s strong financial health and the potential for additional agreements that could further improve its financial outlook. Champions Oncology has also reaffirmed its full-year revenue growth guidance of 10-15%, suggesting a positive trajectory for future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.